Clinical trials: Recurrent Cancer
Melanoma (Skin), Metastatic Cancer
S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Stereotactic radiosurgery may kill more tumor cells.
- Trial name
- NCT00003911
- Testing
- stereotactic radiosurgery
- Where
- 86 sites in United States
- Volunteers
- 2 people
- Sponsor
- SWOG Cancer Research Network
Neuroblastoma
Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma
The purpose of this study is to determine the best dose of imetelstat when given alone for patients with neuroblastoma and also when given in combination with 13-cis-retinoic acid.
- Trial name
- NCT01916187
- Testing
- Imetelstat
- Where
- Canada
- Sponsor
- NCIC Clinical Trials Group
Surgery, Pediatric ALL
Analysis of the Causes of Redo Pull-through for Recurrent Constipation and the Risk Factors Affecting the Prognosis of the Hirschsprung's Disease and Allied Disorders
The goal of this observational study is to conducted a comprehensive analysis of the factors contributing to redo- Pull-through surgery for constipation recurrence in Children who are suffering from Hirschsprun' s disease (HSCR)…
- Trial name
- NCT06175598
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Feng Jiexiong
Sarcoma
Patient-Derived Xenograft (PDX) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma
Patients with recurrent or metastatic sarcoma will be consented to develop a patient derived xenograft (PDX or TumorGraft) model of their tumor to perform drug sensitivity testing.
- Trial name
- NCT02720796
- Testing
- PDX drug sensitivity testing
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- Champions Oncology
Cachexia, Lymphoma
Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer
RATIONALE: Nutritional supplements may help prevent loss of appetite, weight loss, and fatigue in patients with advanced cancer.
- Conditions
- Cachexia, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00053053
- Testing
- Juven, Non-Juven Supplement
- Where
- 250 sites in United States, Canada
- Volunteers
- 472 people
- Sponsor
- Radiation Therapy Oncology Group
Neoplasm of Bone
Study of Anlotinib in Patients With Primary Malignant Bone Tumors
To evaluate the safety and efficacy of patients with recurrent and metastatic bone tumors.
- Trial name
- NCT03527888
- Testing
- Anlotinib
- Where
- 6 sites in China
- Volunteers
- 40 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Stage IVB Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma
Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Infusing melphalan directly to the tumor may kill more tumor cells and cause less damage to healthy tissues.
- Conditions
- Stage IVB Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma, Stage IIC Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma
- Trial name
- NCT00019968
- Testing
- melphalan, tumor necrosis factor
- Sponsor
- National Institutes of Health Clinical Center (CC)
Brain and Central Nervous System Tumors, Lymphoma
Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
- Trial name
- NCT00053118
- Testing
- filgrastim, carboplatin, etoposide
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Roswell Park Cancer Institute
Ovarian Cancer, Primary Peritoneal Cancer
PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer
The goal of this clinical research study is to find the highest safe dose of PS-341 that can be given with carboplatin chemotherapy as a treatment for patients with ovarian, abdominal, or fallopian tube cancer.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT00059618
- Testing
- PS-341 (Bortezomib), Carboplatin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Osteosarcoma, Recurrent Osteosarcoma
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
This phase II trial studies how well denosumab works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory).
- Conditions
- Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Stage IV Osteosarcoma AJCC v7
- Trial name
- NCT02470091
- Testing
- Denosumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 141 sites in United States, Canada and 1 more
- Volunteers
- 56 people
- Sponsor
- Children's Oncology Group
Leukemia, Lymphoblastic, Acute, Leukemia, Myeloid Acute
Phase I, Dose Escalation Study of Decitabine
Decitabine is a hypomethylating agent that has shown significant anti-leukemic effect in Myelodysplastic Syndrome (MDS) and Acute Myeloblastic Leukemia (AML).
- Conditions
- Leukemia, Lymphoblastic, Acute, Leukemia, Myeloid Acute, Hematopoetic Myelodysplasia
- Trial name
- NCT02264873
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Florida
Breast Cancer
High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with chemotherapy may kill more tumor cells.
- Trial name
- NCT00002837
- Testing
- Filgrastim (G-CSF), Cyclophosphamide, Doxorubicin Hydrochloride
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Diarrhea, Drug/Agent Toxicity by Tissue/Organ
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma
- Trial name
- NCT00093353
- Testing
- cefixime, irinotecan hydrochloride, temozolomide
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
This phase II trial studies how well dinutuximab works when given with sargramostim in treating patients with osteosarcoma that has come back after treatment (recurrent).
- Conditions
- Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma
- Trial name
- NCT02484443
- Testing
- Dinutuximab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 130 sites in United States, Australia and 3 more
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Chemotherapeutic Agent Toxicity, Fatigue
First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chemotherapeutic Agent Toxicity, Fatigue, Lung Cancer, Musculoskeletal Complications
- Trial name
- NCT01097317
- Testing
- carboplatin, vinorelbine tartrate, neuromuscular electrical stimulation
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- Wales Cancer Trials Unit
Lymphomas, Tumors
Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy
Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan, with weekly vincristine, temozolomide and vantin; to evaluate the feasibility of repetitive cycles of this chemotherapy and to estimate the…
- Trial name
- NCT00222443
- Testing
- Irinotecan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Oklahoma
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
This phase III trial compares the effect of xylitol dental wipes to dental wipes without xylitol for the reduction of bloodstream infection in children with acute myeloid leukemia (AML).
- Trial name
- NCT07022678
- Testing
- Best Practice, Biospecimen Collection, Cytarabine
- Where
- 39 sites in United States
- Volunteers
- 556 people
- Sponsor
- Children's Oncology Group
Prostate Cancer
Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00002874
- Testing
- bicalutamide, radiation therapy
- Where
- 240 sites in United States, Canada
- Volunteers
- 840 people
- Sponsor
- Radiation Therapy Oncology Group
Melanoma (Skin)
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00079144
- Testing
- NY-ESO-1 peptide vaccine, aldesleukin, filgrastim
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
This clinical trial studies radiolabeled glass beads (yttrium Y 90 glass microspheres) in treating patients with unresectable hepatocellular carcinoma.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT02072356
- Testing
- yttrium Y 90 glass microspheres, laboratory biomarker analysis, TheraSphere
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.